16-18 July 2018 | Boston

 

Speakers

Expand/Collapse

David A. Largaespada, PhD
Chief Scientific Officer
Surrogen, a division of Recombinetics

Thomas Isett
CEO
Hera Biolabs

Tseten Jamling
VP of Research and Development
Hera BioLabs, Inc.

Esmaiel Jabbari
Professor of Chemical & Biomedical Engineering
University of South Carolina

Dr. Jabbari is a Tenured Full Professor of Chemical and Biomedical Engineering and the Director of Biomaterials, Tissue Engineering and Drug Delivery at the University of South Carolina. He earned his Ph.D. from Purdue University in Chemical Engineering. Jabbari’s research is focused on engineering 3D multi-cellular co-culture systems to study and the effect of factors in the microenvironment on  function and fate of stem cells in tissue regeneration and cancer therapy. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of AIMBE in 2013. He has published >250 books, book chapters, refereed journal articles (107 peer-reviewed), and conference proceedings, and presented >260 seminars at national and international conferences (67 plenary, keynote, and invited seminars).

Workshop D

Monday, July 16th 2018

13.00 | Tackling Resistance, Examining The Drug Responses Of Cancer Stem Cells In The Context Of Their Niche

Shanthi Ganesh
Associate Director - Pre Clinical Oncology
Dicerna Pharmaceuticals

Mithun Khattar
Scientist & Immuno- Oncology Lead
Takeda

Day One

Tuesday, July 17th 2018

09.00 | Pre-clinical Modeling of Immune Responses to Cancer: From Bench- Side to Clinical Outcomes

Hon Leong
Associate Associate ProfessorProfessor
Mayo Clinic

Workshop B

Monday, July 16th 2018

09.00 | Next Generation Patient Avatar Systems to Maximize Immunotherapy Benefits

Fu Li
Principal Scientist, Immunology
Seattle Genetics

Wen Lin
Senior Investigator I
Novartis Institutes for BioMedical Research

Matthew Lowerison
Postdoctoral Fellow
Mayo Clinic

Neil Michaud
Associate Director - Translational Medicine
EpiZyme

William Muller
Professor, Biochemistry
McGill University

Christopher L. Murriel
Associate Director, Research
OncoMed Pharmaceuticals, Inc.

Shuji Ogino
Chief of Program in MPE Molecular Pathological Epidemiology & Professor
Brigham & Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Broad Institute of MIT & Harvard

H. Toni Jun
Director of Scientific Engagement
Crown Bioscience

Day One

Tuesday, July 17th 2018

08.30 | Developing Checkpoint Target Humanized Models for Pre-clinical Efficacy Assessment

Daniel Powell
Associate Professor of Pathology & Laboratory Medicine
University of Pennsylvania, School of Medicine

Day Two

Wednesday, July 18th 2018

08.30 | Developing a Universal Immune Receptor Platform for Cancer Targeting

John Rhoden
Senior Research Scientist
Eli Lilly & Co

John M. Ruppert
MD PhD; Professor of Biochemistry & Jo and Ben Statler Chair of Breast Cancer Research
West Virginia University School of Medicine

Fangxian Sun
Lead Investigator - Research Pharmacology
Sanofi

David Teachey
Associate Professor of Paediatrics, Divisions of Haematology and Oncology
Children’s Hospital of Philadelphia

Alejandro Amador
Scientific Leader
GlaxoSmithKline

Jenni Bernoulli
Chief Operating Officer
Pharmatest Services

Michael Brehm
Associate Professor - Molecular Medicine
University of Massachusetts Medical School

Tom Brennan
Vice President, Pharmacology & Bioanalytics
Five Prime Therapeutics

Day Two

Wednesday, July 18th 2018

09.00 | Profiling Murine Tumor Models to Improve Translational Predictive Confidence for Immune-Based Therapeutics

Stephanie Busch
Scientist
uno Therapeutics

Zhao Chen
Investigator III
Genomics Institute of the Novartis Research Foundation (GNF)

Maryland Franklin
Vice President - Scientific Development
MI Bioresearch

Dmitry Gabrilovich
Professor & Program Leader - Translational Tumor Immunology Program
The Wistar Institute

Mark Whitmore
Principal Scientist
Alkermes

Konrad Gabrusiewicz
Scientist II
Bellicum Pharmaceuticals

Susan Mockus
Associate Director of Clinical Genomic Market Development
The Jackson Laboratory for Genomic Medicine

Dr. Mockus is the Associate Director of Clinical Genomic Market Development at The Jackson Laboratory for Genomic Medicine, where she pioneered the development of a clinical knowledgebase (JAX-CKBTM, jax.org/ckb) to support interpretation of cancer next-generation sequencing data. Dr. Mockus continues to oversee the JAX clinical interpretation group while developing internal and external partnerships to foster advancements in the capture, analysis, and utilization of big-data. Her focus is on the development of efficient workflow processes and tools for interpretation of NGS assays through close collaboration with software engineers and IT personnel. At the Jackson Laboratory, she applies over ten years of experience in biocuration to enable clinical reporting of genomic sequencing data and has numerous abstracts and publications on the topic. She received her Ph.D. from Wake Forest University in neuroscience with a minor in pharmacology. After completing postdoctoral training in the department of pharmacology at the University of Washington in Seattle, WA, she began her industry career with Biobase (formerly Proteome), where she was the Product Manager of the Human Disease knowledge base. She most recently received her MBA from the Yale School of Management.

Day One

Tuesday, July 17th 2018

09.30 | Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

Saad Kenderian
Assistant Professor of Medicine and Oncology
Mayo Clinic

Day Two

Wednesday, July 18th 2018

09.30 | Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors